RE:RE:RE:RE:RE:RE:RE:Employee reviewsThanks for that, ScienceFirst. That's very interesting research. But, like you say, it's very early days and the procedure has certain limitations. They attach a specific anti-body-like molecule to a PS, and the conjugate attaches exclusively to target receptors that are overexpressed in EGFR positive GBM cancer cells. They then irradiate with NIR light and besides killing the cancer cells outright it inhibits further EGFRvIII+ve tumor growth. The molecule also fluoresces so it can be used to guide brain surgery. Unfortunately EGFRvIIIpositive GBM cells may only represent a small percentage of cancer cells.
In the 2018 study they do not seem to be aware of other targeted pdt approaches such as Theralase's use of molecules that attach to transferrin receptors that are overexpressed in cancer cells (Rurtherrin). They are also unaware of the fact that Theralase has overcome the photosensitivity issue.
"In recent years, there has been considerable interest surrounding antibodybased PDT, also called photoimmunotherapy (PIT), which utilizes the targeting ability of a highly specific monoclonal antibody (mAb) conjugated to a PS. Following excitation with NIR light, the PS generates reactive oxygen species (ROS), which cause cytotoxic effects exclusively in cancer cells aberrantly overexpressing the target receptors and sparing adjacent normal tissues.15 Conversely, conventional PDT, while effective in inducing cell death, employs nontargeted PSs that affect noncancerous cells, relying entirely on physical targeting by localized optical irradiation, which limits their clinical application due to side effects (e.g., cutaneous photosensitivity).16 Accordingly, PIT applied during GBM surgery could be used as an adjuvant strategy, allowing the surgeon not only to visualize fluorescently positive margins or microscopic residual lesions, but also to eradicate residual or surgically inaccessible tumor cells." Nearinfrared photoimmunotherapy targeting EGFR—Shedding new light on glioblastoma treatment ScienceFirst wrote: FGPStock ... Your post was one of a short-sighted guy. Sad that you missed another opportunity to be more appreciative of TLT's work.
Take a look and notice the multi-disciplinary work. Not the success of just a chemist. Notice also that they are still in the mice animal model.
And notice how Roger was a visionary and how Theralase is year ahead of them.
https://amp.theguardian.com/society/2022/jun/17/scientists-harness-light-therapy-to-target-and-kill-cancer-cells-in-world-first
Scientists have successfully developed a revolutionary cancer treatment that lights up and wipes out microscopic cancer cells, in a breakthrough that could enable surgeons to more effectively target and destroy the disease in patients.
A European team of engineers, physicists, neurosurgeons, biologists and immunologists from the UK, Poland and Sweden joined forces to design the new form of photoimmunotherapy.
Experts believe it is destined to become the world’s fifth major cancer treatment after surgery, chemotherapy, radiotherapy and immunotherapy.
The light-activated therapy forces cancer cells to glow in the dark, helping surgeons remove more of the tumours compared with existing techniques – and then kills off remaining cells within minutes once the surgery is complete. In a world-first trial in mice with glioblastoma, one of the most common and aggressive types of brain cancer, scans revealed the novel treatment lit up even the tiniest cancer cells to help surgeons remove them – and then wiped out those left over.